Total Funding
85
64
Total FundingSeed raised
Growth Score
-4 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
78934
Medical Device, SaMD, Software, Neurotechnology, Biofeedback, Neurofeedback
- Scott Burwell: CEO
About the Company
Medical device focused on treating brain circuits that underlie drug craving caused by environmental triggers for drug use addiction healthcare. People in recovery are constantly reminded of drug use by environmental cues (people, places, things linked to prior drug use), remaining a persistent risk for relapse, overdoses, and diminished life
quality. The NeuromarkR platform (headset+software) measures brain signatures of drug craving not currently addressed in gold standard addiction healthcare. NeuromarkR enables targeted interventions to address triggers for craving by tailored psychotherapy that uses Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Treatment (MBT) strategies.
